ROIV — Roivant Sciences Balance Sheet
0.000.00%
- $7.72bn
- $3.33bn
- $29.05m
- 68
- 17
- 40
- 36
Annual balance sheet for Roivant Sciences, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 2,055 | 2,060 | 1,677 | 6,536 | 4,887 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 13.8 | — | 32.7 | 82.8 | — |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 2,187 | 2,147 | 1,799 | 6,732 | 5,000 |
Net Property, Plant And Equipment | 77 | 86.9 | 92.3 | 66 | 101 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 2,590 | 2,585 | 2,390 | 7,222 | 5,437 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 219 | 184 | 272 | 267 | 149 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 792 | 928 | 1,232 | 1,254 | 749 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 1,798 | 1,657 | 1,158 | 5,969 | 4,688 |
Total Liabilities & Shareholders' Equity | 2,590 | 2,585 | 2,390 | 7,222 | 5,437 |
Total Common Shares Outstanding |